ACP
Acuta Capital Partners’s Enliven Therapeutics ELVN Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-265,269
| Closed | -$5.22M | – | 29 |
|
|
2025
Q1 | $5.22M | Sell |
265,269
-2,099
| -0.8% | -$41.3K | 6.05% | 5 |
|
|
2024
Q4 | $6.02M | Sell |
267,368
-29,000
| -10% | -$653K | 6.05% | 5 |
|
|
2024
Q3 | $7.57M | Sell |
296,368
-101,330
| -25% | -$2.59M | 6.13% | 5 |
|
|
2024
Q2 | $9.29M | Buy |
397,698
+1,599
| +0.4% | +$37.4K | 7.83% | 2 |
|
|
2024
Q1 | $6.97M | Buy |
396,099
+272,223
| +220% | +$4.79M | 4.53% | 8 |
|
|
2023
Q4 | $1.71M | Buy |
123,876
+20,276
| +20% | +$281K | 0.97% | 28 |
|
|
2023
Q3 | $1.42M | Sell |
103,600
-900
| -0.9% | -$12.3K | 0.95% | 27 |
|
|
2023
Q2 | $2.13M | Buy |
104,500
+73,521
| +237% | +$1.5M | 1.45% | 23 |
|
|
2023
Q1 | $678K | Sell |
30,979
-13,524
| -30% | -$296K | 0.5% | 25 |
|
|
2022
Q4 | $182K | Buy |
+44,503
| New | +$182K | 0.11% | 32 |
|